🟢 Context Therapeutics is trading 7% up in after-hours trading with no clear company-specific catalyst

Context Therapeutics is trading 7.02% up at $0.38 after the September 11, 2026 regular session closed at $0.35; the move appears aligned with broader risk-on sentiment.

• No new company-specific announcement was identified for September 11.
• The latest listed release was September 9 and concerned first patient dosing in the CT-202 Phase 1 trial.
• Major U.S. indices gained more than 0.5%; the September 9 update does not clearly explain the after-hours move.